Ligand Pharmaceuticals (LGND) Other Operating Expenses (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 16 years of Other Operating Expenses data on file, last reported at $11.4 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses fell 10.21% year-over-year to $11.4 million; the trailing twelve-month figure through Mar 2026 stood at $52.2 million (up 3.66% YoY), and the FY2023 full-year result was $2.1 million, changed N/A from the prior year.
• Other Operating Expenses eased to $11.4 million in Q1 2026, from $17.3 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $37.7 million in Q2 2024 to a low of $2.1 million in Q3 2023.
• A 5-year average of $13.8 million and a median of $12.3 million in 2023 frame the typical range for Other Operating Expenses.
• Across the five-year window, Other Operating Expenses jumped 268.87% in 2024 and tumbled 66.96% in 2025, its largest moves.
• Tracing LGND's Other Operating Expenses over 5 years: stood at $13.3 million in 2022, then slumped by 84.03% to $2.1 million in 2023, then surged by 1675.29% to $37.7 million in 2024, then plunged by 54.1% to $17.3 million in 2025, then slumped by 34.22% to $11.4 million in 2026.
• Business Quant data shows LGND's Other Operating Expenses at $11.4 million in Q1 2026, $17.3 million in Q4 2025, and $11.1 million in Q3 2025.